Lipocine (LPCN) Liabilities and Shareholders Equity (2011 - 2025)

Lipocine (LPCN) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $17.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 24.45% year-over-year to $17.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $72.2 million (down 21.3% YoY) and the FY2025 annual result came in at $17.0 million, down 24.45% from the prior year.
• Liabilities and Shareholders Equity advanced to $17.0 million in Q4 2025, from $16.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $52.5 million in Q4 2021 to a low of $16.1 million in Q3 2025.
• A 5-year average of $31.7 million and a median of $28.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 140.93% — and 2023, when it slumped 38.73%.
• Tracing LPCN's Liabilities and Shareholders Equity over 5 years: stood at $52.5 million in 2021, then fell by 28.47% to $37.5 million in 2022, then tumbled by 38.73% to $23.0 million in 2023, then slipped by 2.13% to $22.5 million in 2024, then decreased by 24.45% to $17.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $17.0 million (Q4 2025), $16.1 million (Q3 2025), and $18.6 million (Q2 2025), per Business Quant data.